MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during treatment of plaque psoriasis with bimekizumab.
Bimekizumab
COVID19 vaccination
IL17 antibody
MPO-ANCA
Psoriasis
RPGN
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
01
04
2024
accepted:
26
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
A 75-year-old man presented with MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during the treatment of plaque psoriasis vulgaris with bimekizumab. Bimekizumab, an anti-IL17 monoclonal antibody, was regularly administered to control the activity of plaque psoriasis. After receiving the sixth COVID-19 vaccine, his kidney function rapidly declined over the course of weeks. Urinalysis showed microscopic hematuria and proteinuria with deformed red blood cells and granular cast. The immunology test was positive for MPO-ANCA. The patient was clinically diagnosed with MPO-ANCA-associated glomerulonephritis. As the patient lost his appetite and developed lower extremity edema with low eGFR (< 15 ml/min/1.73m
Identifiants
pubmed: 39297892
doi: 10.1007/s13730-024-00927-6
pii: 10.1007/s13730-024-00927-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.
Références
Hogan JJ, Markowitz GS, Radhakrishnan J. Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol. 2015;10:1300–10.
doi: 10.2215/CJN.01910215
pubmed: 26092827
pmcid: 4491282
Santoriello D, et al. Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney Int. 2021;100:440–6.
doi: 10.1016/j.kint.2021.03.029
pubmed: 33857570
Chen CH, Wu MJ, Tsai SF. Safety and effectiveness of COVID-19 vaccines in patients with IgA nephropathy: a retrospective cohort study from the TriNetX global collaborative networks. EClinicalMedicine. 2023;65: 102306.
doi: 10.1016/j.eclinm.2023.102306
pubmed: 38021374
pmcid: 10661495
J. Irure-Ventura et al., Increased induction of de novo serum ANCA and ANCA-associated vasculitis after mass vaccination against SARS-CoV-2. iScience 25, 104847 (2022).
Grewal SK, et al. The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2017;176:1366–9.
doi: 10.1111/bjd.14961
pubmed: 27518038
pmcid: 5303688
Perkovic D, Simac P, Katic J. IgA vasculitis during secukinumab therapy. Clin Rheumatol. 2021;40:2071–3.
doi: 10.1007/s10067-020-05364-1
pubmed: 32860543
Segawa Y, et al. IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis. BMC Nephrol. 2020;21:366.
doi: 10.1186/s12882-020-02015-0
pubmed: 32842976
pmcid: 7449059
Windpessl M, et al. COVID-19 vaccines and kidney disease. Nat Rev Nephrol. 2021;17:291–3.
doi: 10.1038/s41581-021-00406-6
pubmed: 33558753
pmcid: 7869766
Diebold M, et al. Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased. Kidney Int. 2022;102:1409–19.
doi: 10.1016/j.kint.2022.08.021
pubmed: 36096267
pmcid: 9462927
Shakoor MT, Birkenbach MP, Lynch M. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78:611–3.
doi: 10.1053/j.ajkd.2021.06.016
pubmed: 34280507
pmcid: 8285210
Suzuki M, et al. Antineutrophil Cytoplasmic antibody-associated vasculitis after COVID-19 vaccination with Pfizer-BioNTech. Intern Med. 2022;61:2925–9.
doi: 10.2169/internalmedicine.9807-22
pubmed: 36184535
pmcid: 9593166
Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int. 2021;100:473–4.
doi: 10.1016/j.kint.2021.05.017
pubmed: 34081948
pmcid: 8166044
Campos MAG, et al. ANCA-associated glomerulonephritis and lupus nephritis following COVID-19 vaccination: a case report and literature review. Front Immunol. 2023;14:1298622.
doi: 10.3389/fimmu.2023.1298622
pubmed: 38299140
Canney M, et al. A population-based analysis of the risk of glomerular disease relapse after COVID-19 Vaccination. J Am Soc Nephrol. 2022;33:2247–57.
doi: 10.1681/ASN.2022030258
pubmed: 36332971
pmcid: 9731636
M. Ochi et al., in CEN Case Rep. (Japan, 2019), vol. 8, pp. 200–204.
Ozince RB, Ak T, Erzin YZ, Melikoglu M, Seyahi E. Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis. Int J Rheum Dis. 2023;26:1811–5.
doi: 10.1111/1756-185X.14667
pubmed: 36929128
Lavoz C, et al. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. Kidney Int. 2019;95:1418–32.
doi: 10.1016/j.kint.2018.12.031
pubmed: 30982673
Mehrotra P, et al. IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion: compensatory role of natural killer cells in athymic rats. Am J Physiol Renal Physiol. 2017;312:F385-f397.
doi: 10.1152/ajprenal.00462.2016
pubmed: 27852609
Velden J, et al. Renal IL-17 expression in human ANCA-associated glomerulonephritis. Am J Physiol Renal Physiol. 2012;302:F1663-1673.
doi: 10.1152/ajprenal.00683.2011
pubmed: 22442208
Nogueira E, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2010;25:2209–17.
doi: 10.1093/ndt/gfp783
pubmed: 20100727
Gan PY, et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol. 2010;21:925–31.
doi: 10.1681/ASN.2009070763
pubmed: 20299361
pmcid: 2900960